Notably, the patient (P2) who received multiple EGFR TKIs likely acquired FGFR3 R248C and/or G380R to overcome the anti-tumor activity of TKIs, including osimertinib and afatinib, although pretreatment samples were unfortunately not available (Table 1). This evidence concerns the gene FGFR3 and neoplasm.